Crucell « Terug naar discussie overzicht

12 maart in Londen !!

175 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 » | Laatste
[verwijderd]
0
Crucell Presents a Compelling Case for Investment at Investor and Analyst Day in London


London, March 12, 2008 - Dutch biopharma company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) today presents an update on the company's performance, strategy for growth acceleration and a review of the company's pipeline at a meeting for investors and analysts in London. A live audio webcast of the meeting, together with the program and slides of all presentations, will be available on Crucell's website at www.crucell.com.

Presentations given by senior management and program managers outline a compelling case for investment in Crucell, based on significant solid growth of the company's vaccines business. Furthermore Crucell enjoys a pipeline of multiple products tailored to address major threats to health and well-being worldwide as well as strong partnerships in vaccine and antibody research. Crucell's portfolio of unique technologies generating licensing income as well as driving Crucell's in-house R&D and manufacturing programs will also be discussed.

A clear focus on achieving operational excellence is an integral part of Crucell's strategy for accelerating growth. A rigorous review of Crucell's business processes worldwide is being conducted and savings of approximately 15%*[1] on the 2007 cost base are being targeted.

Rationalization is one aspect of Crucell's 'Healthy Ambition' program, which is being implemented throughout the global organization in order to further strengthen the financial health of the company. Cash generated by streamlining business processes and making full use of synergies within the integrated organization will fuel further R&D in targeted areas, thereby enhancing Crucell's ability to significantly improve human health.

Crucell's strategic focus remains firmly on fighting infectious diseases through the development, manufacturing and sale of innovative vaccines and antibodies. Infectious diseases represent a major health burden and their impact will increase due to trends such as climate change, globalization, and aging.

In line with its focused strategy, Crucell has said that the research program into the recombinant antibody Factor VL/C, as a potential therapy to stop or prevent serious bleeding, has proven to be more challenging than previously anticipated and preclinical research provided mixed results and insufficient evidence of the protective benefit of Factor VL/C as a stand-alone therapeutic product. It is therefore not expected that the program will go into the clinic in the foreseeable future and the research and development expenditure previously earmarked for this program will now be largely allocated to the research & development of monoclonal antibodies.

Crucell is already the largest independent player in the vaccine business, with sales and other income in 60 countries totalling €213 million in 2007. Strong autonomous growth in 2007 was driven by the successful launch of Quinvaxem(TM) vaccine, the only fully-liquid pentavalent (five in one shot) vaccine against five potentially deadly childhood diseases as well as solid growth from travel vaccines. In 2008 the overall business is expected to grow a further 20%*[2]. Quinvaxem(TM) will be the biggest driver of this growth and is expected to grow at a faster rate than the business as a whole.

Significant growth in sales of Crucell's marketed products comes from substantial opportunities for launching its portfolio of current vaccines in new markets and growing sales in existing markets. This portfolio includes vaccines for protection against pediatric illnesses (Quinvaxem(TM) pentavalent vaccine, Epaxal® Junior hepatitis A vaccine, Hepavax-Gene® hepatitis B vaccine); travel and endemic diseases (Epaxal® in adult and junior formulations, Vivotif® typhoid vaccine, Dukoral® cholera vaccine); and respiratory illness (Inflexal V® influenza vaccine).

Crucell's growth strategy also includes intensive R&D efforts to ensure solid progress in clinical development. Both vaccine and antibody research is being focused on combating infectious diseases, with an emphasis on the existing categories of pediatric, travel/endemic and respiratory illnesses. High-priority programs showing promising results in clinical trials include vaccines against malaria and tuberculosis, and a monoclonal antibody (mAb) cocktail against rabies. Detailed updates on these programs and on Crucell's core technologies are being presented during the afternoon of the Investor and Analyst Day.

[verwijderd]
0
Zie sheet 38 voor stand van zaken rond de korean plant. Wel iets aan de hand, maar de fabriek gaat niet plan volgend jaar.
maxen
0
!!!
Niet goed !!!

quote:

robertix schreef:


In line with its focused strategy, Crucell has said that the research program into the recombinant antibody Factor VL/C, as a potential therapy to stop or prevent serious bleeding, has proven to be more challenging than previously anticipated and preclinical research provided mixed results and insufficient evidence of the protective benefit of Factor VL/C as a stand-alone therapeutic product. It is therefore not expected that the program will go into the clinic in the foreseeable future and the research and development expenditure previously earmarked for this program will now be largely allocated to the research & development of monoclonal antibodies.
[verwijderd]
0
Datum Omschrijving
12-03-2008 10:05:14 CRUCELL ZIET OMZETSTIJGING 20% IN 2008
12-03-2008 10:04:47 CRUCELL: GEEN KLINISCHE STUDIE FACTOR VL/C NABIJE TOEKOMST
12-03-2008 10:04:05 CRUCELL ZET REGIOUREUZE 'REVIEW' BUSINESSPROCESSEN IN GANG
12-03-2008 10:03:24 CRUCELL WIL KOSTENBESPARINGEN VAN CA. 15% TOV 2007
flosz
0
quote:

flosz schreef:



Misschien kan Cees de Jong "iets" vertellen over operational spoorlijntje?
(Light railway, a subway line extension and a transfer station between those two transit lines.)




Korean site update production-continuity good despite construction activities

Property leased until 2010; extension for 5 years possible
Korean Green Cross Corporation (lessor) provides certain utilities
Construction of subway and light railway started
Landlord will vacate the property in 2009 to enable further urban development
Crucell is creating own utilities
Although Crucell property not in the way of the subway and/or railway project, preparing eventual move to other location
[verwijderd]
0
quote:

maxen schreef:


!!!
Niet goed !!!

[quote=robertix]
In line with its focused strategy, Crucell has said that the research program into the recombinant antibody Factor VL/C, as a potential therapy to stop or prevent serious bleeding, has proven to be more challenging than previously anticipated and preclinical research provided mixed results and insufficient evidence of the protective benefit of Factor VL/C as a stand-alone therapeutic product. It is therefore not expected that the program will go into the clinic in the foreseeable future and the research and development expenditure previously earmarked for this program will now be largely allocated to the research & development of monoclonal antibodies.
[/quote]

Ik zeg net hetzelfde tegen ivet, idd........
[verwijderd]
0
quote:

rob007 schreef:


Datum Omschrijving
12-03-2008 10:05:14 CRUCELL ZIET OMZETSTIJGING 20% IN 2008
12-03-2008 10:04:47 CRUCELL: GEEN KLINISCHE STUDIE FACTOR VL/C NABIJE TOEKOMST
12-03-2008 10:04:05 CRUCELL ZET REGIOUREUZE 'REVIEW' BUSINESSPROCESSEN IN GANG
12-03-2008 10:03:24 CRUCELL WIL KOSTENBESPARINGEN VAN CA. 15% TOV 2007


Ik mis er 1, waarin staat dat quinvaxem de grootste groei aanjager wordt?
Nou als dat de grootste aanjager wordt......
aossa
0
quote:

Nx4nX schreef:


Zie sheet 38 voor stand van zaken rond de korean plant. Wel iets aan de hand, maar de fabriek gaat niet plan volgend jaar.


Korean site update production-continuity good despite construction activities

•Property leased until 2010; extension for 5 years possible

•Korean Green Cross Corporation (lessor) provides certain utilities

•Construction of subway and light railway started

•Landlord will vacate the property in 2009 to enable further urban development

•Crucell is creating own utilities

•Although Crucell property not in the way of the subway and/or railway project, preparing eventual move to other location
flosz
0
quote:

robertix schreef:


[quote=maxen]
!!!
Niet goed !!!

[quote=robertix]
In line with its focused strategy, Crucell has said that the research program into the recombinant antibody Factor VL/C, as a potential therapy to stop or prevent serious bleeding, has proven to be more challenging than previously anticipated and preclinical research provided mixed results and insufficient evidence of the protective benefit of Factor VL/C as a stand-alone therapeutic product. It is therefore not expected that the program will go into the clinic in the foreseeable future and the research and development expenditure previously earmarked for this program will now be largely allocated to the research & development of monoclonal antibodies.
[/quote]
[/quote]
Ik zeg net hetzelfde tegen ivet, idd........


In vitro proof of concept that rFVL/C can be used to
correct the functional absence of FVIII

Conclusion pre-clinical assessment of Factor FVL/C

In vitro
FVL/C corrects clotting defect of hemophilic plasma
In vivo

FVL/C needs FVIII to correct hemophilic bleeding in FVIII deficient mice
Consequences for use in hemophiliacs

Use of FVL/C would be restricted to hemophiliacs without inhibitors against FVIII, thereby excluding prime target indication
aossa
0
quote:

aossa schreef:


•Korean Green Cross Corporation (lessor) provides certain utilities

•Construction of subway and light railway started

•Landlord will vacate the property in 2009 to enable further urban development

•Crucell is creating own utilities

•Although Crucell property not in the way of the subway and/or railway project, preparing eventual move to other location


Imo gaat het niet om 'ontruimen' van de faciliteit, maar om voortijdig onderbreken van de nutsvoorzieningen. Crucell gaat zelf zorgen voor die nutsvoorzieningen (water, electriciteit, gas, riool etc. ?) zodat ze hiervan niet van de Landeigenaar afhangt.
maxen
0
quote:

aossa schreef:


[quote=aossa]
...
•Although Crucell property not in the way of the subway and/or railway project, preparing eventual move to other location
[/quote]

Imo gaat het niet om 'ontruimen' van de faciliteit, maar om voortijdig onderbreken van de nutsvoorzieningen. Crucell gaat zelf zorgen voor die nutsvoorzieningen (water, electriciteit, gas, riool etc. ?) zodat ze hiervan niet van de Landeigenaar afhangt.


Klopt, maar laatste zin geeft wel degelijk aan dat Crucell ondanks-niet-in-de-weg-zitten alsnog een verhuizing voorbereidt.
[verwijderd]
0
[verwijderd]
0
quote:

BAC55 schreef:


Lekker negatief he.

Al


Waar blijven de pessimisten nu???? Ik had toch gezegd dat we gingen stijgen, maar onze pessimisten geloofden het niet!!! Ik denk dat ze nu zitten te huilen met hun shortjes, maar nu ga ik eens lachen.
[verwijderd]
0
Slecht nieuws Factor V en de koers stijgt. Geeft alleen maar aan dat fundamentals de koers niet bepalen; dat doen de grote jongens. Die bepalen de richting.
[verwijderd]
0
quote:

Japies schreef:


Slecht nieuws Factor V en de koers stijgt. Geeft alleen maar aan dat fundamentals de koers niet bepalen; dat doen de grote jongens. Die bepalen de richting.


Koers reageert toch voornamlijk op news dat op KT leidt tot winstgevendheid. Factor V is MT/LT.
flosz
0
quote:

money1234 schreef:


[quote=BAC55]
Lekker negatief he.

Al
[/quote]

Waar blijven de pessimisten nu???? Ik had toch gezegd dat we gingen stijgen, maar onze pessimisten geloofden het niet!!! Ik denk dat ze nu zitten te huilen met hun shortjes, maar nu ga ik eens lachen.

Ipv kwaken is het ook mogelijk te luisteren en te lezen! (Eventueel begrijpen).
Procambarus
0
Nog eventjes en er moeten short posities worden gladgestreken. Dat kan de koers vandaag nog boven €10 brengen!
175 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 1 jan 0001 00:00
Koers 0,000
Verschil 0,000 (0,00%)
Hoog 0,000
Laag 0,000
Volume 0
Volume gemiddeld 0
Volume gisteren 0